FDA platform designation decisions keep LGMD patients waiting for gene therapy

In a personal essay, a limb-girdle muscular dystrophy patient describes the promise of gene-therapy advances and the regulatory framework created by the 2022 Food and Drug Omnibus Reform Act, which lets the FDA assign platform technology designations to shared viral vectors. Sarepta received such a designation for the vector behind its LGMD2E/R4 therapy, but the FDA revoked it and halted all trials after three non-ambulatory patients—two with Duchenne and one with LGMD2D/R3—died.

Although dosing later resumed for the Duchenne indication in ambulatory patients, the LGMD study stays on clinical hold, leaving patients without access while their condition progresses. The author points to earlier FDA holds on gene therapies for Hurler and Hunter syndromes, where risk was extrapolated across diseases despite differing safety data. These patterns, the author argues, create uncertainty for rare-disease developers and delay potential treatments, prompting a call for clearer guidance and congressional oversight.